JPMorgan Chase & Co. Issues Positive Forecast for Axon Enterprise (NASDAQ:AXON) Stock Price

Axon Enterprise (NASDAQ:AXON) had its target price boosted by JPMorgan Chase & Co. from $750.00 to $755.00 in a research note published on Thursday morning,Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

AXON has been the topic of a number of other reports. UBS Group lowered their price target on Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a report on Thursday. TD Cowen reduced their price objective on shares of Axon Enterprise from $950.00 to $825.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Citizens Jmp lowered their target price on shares of Axon Enterprise from $825.00 to $700.00 and set a “market outperform” rating on the stock in a report on Thursday. Royal Bank Of Canada reduced their price target on shares of Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating on the stock in a report on Wednesday, February 25th. Finally, Morgan Stanley set a $600.00 price objective on shares of Axon Enterprise in a report on Thursday. Sixteen investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and a consensus target price of $712.75.

Axon Enterprise Stock Performance

Axon Enterprise stock traded down $32.64 during midday trading on Thursday, hitting $394.25. The stock had a trading volume of 1,045,698 shares, compared to its average volume of 1,060,959. Axon Enterprise has a 52-week low of $339.01 and a 52-week high of $885.91. The company has a market capitalization of $31.77 billion, a PE ratio of 158.16, a P/E/G ratio of 8.24 and a beta of 1.44. The firm’s fifty day moving average is $451.93 and its two-hundred day moving average is $527.52. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. The business had revenue of $807.35 million during the quarter, compared to analyst estimates of $778.91 million. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.95%. The company’s revenue was up 33.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.47 earnings per share. On average, research analysts forecast that Axon Enterprise will post 1.41 EPS for the current year.

Insider Transactions at Axon Enterprise

In related news, CAO Jennifer H. Mak sold 1,500 shares of Axon Enterprise stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the transaction, the chief accounting officer owned 12,240 shares in the company, valued at approximately $7,019,028. This trade represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Erika Nardini sold 198 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the sale, the director owned 1,946 shares in the company, valued at approximately $985,804.68. This trade represents a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,855 shares of company stock valued at $7,109,828 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AXON. Vicus Capital boosted its stake in shares of Axon Enterprise by 3.7% during the 3rd quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after purchasing an additional 14 shares during the period. Evergreen Capital Management LLC raised its position in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 15 shares during the period. NorthCrest Asset Manangement LLC lifted its stake in Axon Enterprise by 5.4% in the third quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 16 shares during the last quarter. WPG Advisers LLC boosted its position in shares of Axon Enterprise by 9.8% during the third quarter. WPG Advisers LLC now owns 190 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 17 shares during the period. Finally, Monte Financial Group LLC grew its stake in shares of Axon Enterprise by 5.5% during the third quarter. Monte Financial Group LLC now owns 325 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 17 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q1 revenue and guidance lift: Axon reported Q1 revenue of ~$807M (up ~34% YoY) and raised FY revenue growth to 30%–32%, reiterating strong cash‑flow targets—this underpins the case for durable growth. Axon reports Q1 2026 revenue of $807 million, up 34% year over year
• Positive Sentiment: AI & counter‑drone acceleration: Management highlighted AI product revenue up ~700% and counter‑drone bookings/revenue growing several hundred percent, helping drive the guidance raise and stronger bookings momentum. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analyst support remains: Several firms maintained or raised bullish ratings (e.g., JPMorgan raised its price target), reflecting continued confidence in Axon’s growth runway. These notes can provide buying interest. Benzinga coverage of analyst actions
• Neutral Sentiment: Municipal order in Baltimore: The city approved a $153M police-equipment contract (body cameras, Tasers), which is incremental revenue and a commercial win but also drew competitive/price scrutiny that could attract political headlines. FOX45: Baltimore approves $153M contract for police equipment
• Neutral Sentiment: Mixed analyst notes and coverage: Media pieces emphasize bullish ARR/AI trends but also debate valuation — this creates two‑sided flows as some investors buy the growth story while others sit on the sidelines. Analysts Conflicted on These Industrial Goods Names
• Negative Sentiment: Margin / EPS pressure: While revenue beat, some coverage flagged an EPS miss vs certain estimates and tariff‑driven margin pressure — a reminder that profitability and cost headwinds matter to investors. AXON Q1 Earnings Miss Estimates on Tariff-Driven Margins
• Negative Sentiment: Short‑term selling and valuation concerns: Despite the beat, shares have pulled back as some investors take profits after recent gains and others focus on a stretched P/E and several trimmed price targets — creating downward pressure. Assessing Axon Enterprise (AXON) Valuation After A Sharp Year To Date Share Price Decline

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.